Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Chain of Custody for Clinical Samples – V 2.0

Posted on By

BA-BE Studies: SOP for Chain of Custody for Clinical Samples – V 2.0

Standard Operating Procedure for Chain of Custody for Clinical Samples in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/077/2025
Supersedes SOP/BA-BE/077/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define a standardized process for maintaining an uninterrupted and verifiable chain of custody for biological samples collected during Bioavailability/Bioequivalence (BA/BE) studies from the point of collection to final analysis or disposal.

2. Scope

This SOP applies to all clinical and laboratory staff responsible for collecting, transporting, storing, transferring, and receiving clinical samples (blood, plasma, serum) during BA/BE studies.

3. Responsibilities

  • Phlebotomist: Ensures initial documentation and transfer of samples post-collection.
  • Lab Technician: Maintains sample receipt, processing, and transfer logs.
  • CRC: Oversees end-to-end documentation and review.
  • QA Officer: Periodically audits chain of custody records for completeness and accuracy.
See also  BA-BE Studies: SOP for Volunteer Screening and Selection Criteria - V 2.0

4. Accountability

The Study Principal Investigator is accountable for ensuring chain of custody procedures are rigorously followed and adequately documented throughout the lifecycle of clinical samples.

5. Procedure

5.1 Sample Identification and Labeling

  1. Label samples immediately after collection with:
    • Subject ID
    • Date and time of collection
    • Timepoint and period
  2. Verify label accuracy with Annexure-1: Sample Receipt and Verification Log.

5.2 Initial Handover and Logging

  1. Phlebotomist hands over collected samples to lab staff within 30 minutes of collection.
  2. Document transfer in Annexure-2: Sample Handover Log including:
    • Date and time
    • Sample condition
    • Recipient signature

5.3 Sample Tracking During Processing

  1. Maintain Annexure-3: Sample Processing Log for centrifugation and aliquoting activities.
  2. Link processing batch numbers and freezer box IDs for traceability.

5.4 Freezer Storage Documentation

  1. Enter sample location in Annexure-4: Freezer Storage Record, capturing:
    • Freezer ID
    • Rack and slot number
    • Date/time of storage

5.5 Inter-Laboratory Transfer (if applicable)

  1. Use validated insulated containers and temperature logs for transfer to bioanalytical site.
  2. Generate Annexure-5: Chain of Custody Transfer Form signed by sender and receiver.
See also  BA-BE Studies: SOP for Monitoring Vital Signs During Clinical Phase - V 2.0

5.6 Sample Disposal or Return

  1. Post-analysis, document either sample return or destruction as per sponsor or regulatory directive.
  2. Maintain Annexure-6: Sample Disposal or Return Record.

5.7 Review and Audit Trail

  1. CRC or QA staff to review chain of custody records weekly during the study phase.
  2. Any missing entry or discrepancy must be resolved and documented via CAPA.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CRC: Clinical Research Coordinator
  • QA: Quality Assurance
  • ID: Identification

7. Documents

  1. Sample Receipt and Verification Log – Annexure-1
  2. Sample Handover Log – Annexure-2
  3. Sample Processing Log – Annexure-3
  4. Freezer Storage Record – Annexure-4
  5. Chain of Custody Transfer Form – Annexure-5
  6. Sample Disposal or Return Record – Annexure-6

8. References

  • ICH E6(R2) – Good Clinical Practice
  • US FDA Guidance for BA/BE Studies
  • 21 CFR Part 58 – GLP Regulations

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department
See also  BA-BE Studies: SOP for Reviewing Reference Product Literature - V 2.0

11. Annexures

Annexure-1: Sample Receipt and Verification Log

Subject ID Timepoint Date/Time Verified By Remarks
VOL-077 2h 17/04/2025, 08:20 R. Pawar Correct

Annexure-2: Sample Handover Log

Sample ID Handover From To Time Condition Signatures
VOL077/P1/2h Phlebotomy Lab 08:25 Intact Ravi / Nisha

Annexure-3: Sample Processing Log

Sample ID Process Time Handled By Remarks
VOL077/P1/2h Centrifugation 08:30 Sunita Reddy Done

Annexure-4: Freezer Storage Record

Sample Code Freezer ID Rack No. Box No. Logged By Date/Time
VOL077/P1/2h/A1 FZ-03 R1 BX04 Ravi Nair 17/04/2025, 09:00

Annexure-5: Chain of Custody Transfer Form

Date From To Samples Condition Sent By Received By
18/04/2025 Clinic Bio Lab VOL077/A1–A4 Frozen Sunita Vikas

Annexure-6: Sample Disposal or Return Record

Date Sample ID Action Reason Authorized By Remarks
20/04/2025 VOL077/A4 Disposed Unused aliquot QA Head Documented

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial release Regulatory requirement QA Head
17/04/2025 2.0 Updated with inter-lab transfer and disposal logs Audit compliance QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Creams: SOP for Operational Checks of Temperature Control Systems – V 2.0
Next Post: API Manufacturing: SOP for Handling of Mixed Solvent Streams – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version